Press release

Anocca Appoints Christiane Hanke-Harloff to Board of Directors

May 31, 2024

SÖDERTÄLJE, SWEDEN, 31 May 2024 – Anocca AB, a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, announces the appointment of Christiane Hanke-Harloff to its Board of Directors.

With a distinguished career spanning the biotechnology, pharmaceutical, and CDMO sectors, Christiane Hanke-Harloff brings a wealth of expertise and strategic insights. Christiane is currently a Board member of InnoCore Pharmaceuticals BV and Ascenion GmbH, former Board member of Recipharm AB and also serves as an advisor for lifescience sector investors and biotech firms. Previously held executive roles at Gilead Sciences, Gedeon Richter and other biotech companies, where she was responsible for organisational strategy and the expansion of international business units. She earned her PhD in molecular biology from the Max Planck Institute of Biochemistry in Martinsried, Germany.

"We’re pleased to welcome Christiane Hanke-Harloff to Anocca's board. Her extensive experience and deep understanding of the industry and CDMO landscape will be invaluable as we navigate our clinical development and manufacturing expansion," said Hans Stråberg, Anocca’s Chairman of the Board.

"Christiane's appointment comes at a pivotal time for Anocca," noted Reagan Jarvis, Co-founder and CEO of Anocca. "Her industry experience will play a valuable supportive role as we progress our TCR-T cell therapies into clinical development for hard-to-treat cancers.”

Christiane Hanke-Harloff stated, "Anocca's innovative approach and comprehensive capabilities spanning research to manufacturing position it as a leader in TCR-T cell therapy. I am excited to collaborate with the team as we advance these groundbreaking therapies into clinical development."

Anocca has been making significant developments in advancing precision TCR-T cell therapies aimed at transforming patient outcomes in hard-to-treat solid tumor indications. With recent achievements including the licensing agreement for use of EmendoBio’s novel gene editing technology, and by securing GMP license for the largest cell-therapy manufacturing facility in the Nordics, the company is accelerating its journey from discovery to clinical development.

About Anocca

Anocca is a fully integrated biopharmaceutical company developing libraries of T cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autommune diseases. Its proprietary technologies have been designed to vastly expand TCR-T cell therapy development, allowing the systematic generation of treatments for the broadest patient populations that equip the immune system against the most difficult to treat solid tumours.

Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem and in-house clinical manufacturing and process development facilities. Its unique discovery platform uses programmable human cells to recreate and manipulate T cell immunity.

Follow Anocca on LinkedIn and visit our new website

Media Inquiries

Anocca AB

Jacob Michlewicz, CFO

Scius Communications (for Anocca AB)

Katja Stout

Tel: +44 7789 435 990

Daniel Gooch

Tel: +44 7747 875 479